- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
Patent holdings for IPC class A61P 3/08
Total number of patents in this class: 1134
10-year publication summary
38
|
46
|
82
|
109
|
105
|
93
|
105
|
71
|
87
|
32
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Janssen Pharmaceutica N.V. | 3432 |
23 |
Boehringer Ingelheim International GmbH | 4701 |
13 |
The Board of Trustees of the Leland Stanford Junior University | 6347 |
13 |
Axcess Global Sciences, LLC | 80 |
13 |
Mymd Pharmaceuticals, Inc. | 32 |
11 |
Sanofi-Aventis Deutschland GmbH | 2638 |
9 |
Alla Chem, LLC | 55 |
9 |
Société des Produits Nestlé S.A. | 9190 |
8 |
The Regents of the University of California | 19803 |
8 |
Eli Lilly and Company | 3809 |
8 |
Inserm (institut National de La Sante et de La Recherche Medicale) | 3361 |
7 |
Regeneron Pharmaceuticals, Inc. | 4223 |
7 |
Novo Nordisk A/S | 2287 |
7 |
Amgen Inc. | 4037 |
6 |
The Trustees of Columbia University in the City of New York | 3558 |
6 |
Hanmi Pharm. Co., Ltd. | 570 |
6 |
Ionis Pharmaceuticals, Inc. | 856 |
6 |
The Salk Institute for Biological Studies | 447 |
6 |
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | 1347 |
6 |
Hua Medicine (Shanghai) Ltd. | 59 |
6 |
Other owners | 956 |